eFFECTOR Therapeutics, Inc.
http://effector.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From eFFECTOR Therapeutics, Inc.
eFFECTOR's Tomiversib Flops In Lung Cancer, Hopes Rest On AML
The company still sees a potential path forward for tomivosertib in acute myeloid leukemia, where its mechanistic rationale is distinct from the one in NSCLC.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
ASCO 2023 – Deep And Early Responses Lift Hopes At Effector
New data with a novel RNA translation regulator gave the stock a pre-ASCO boost, but the micro-cap company needs to keep the momentum going.
Finance Watch: Three Newly Public Companies Face Mixed Reception In Early Trading
Also, two more health care-focused SPACs went public, Centessa obtained up to $300m in debt, three new venture capital funds launched and Intergalactic debuted with a $75m series A round.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Locust Walk Acquisition Corp.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice